New radiopharmaceuticals are and always has been at the heart of nuclear medicine’s contribution to diagnostic imaging.
Recently released in the Journal of Nuclear Medicine’s November issue is an article about researchers who have developed a new nuclear medicine tracer, 99mTc-HYNIC-cMBP. This new tracer could improve diagnosis and treatment of non-small cell lung cancer. According to the article, the 99mTc-HYNIC-cMBP produced clearer images in less time than currently used tracers and was more rapidly eliminated from the body, reducing radiation exposure. The new tracer isn’t ready for human use yet, but it may be if research continues to show good results.